Hemcheck Sweden AB has established an international clinical advisory board. The board will act as advisors to the company with regards to the continued work of building clinical evidence, evaluation of products and future product development. The board will consist of four experts active in the fields of acute medicine, internal medicine, and laboratory medicine. The four experts are Professor Salvatore Di Somma from Rome, Professor Olle Melander from Lund, Professor Jorge Ordonez-Llanos from Barcelona, and Professor Michael Christ from Luzern.

– It’s very important for a company like Hemcheck to have access to strong clinical and scientific expertise and I am convinced that the board will contribute a lot to Hemcheck. I am very happy that we have these distinguished individuals in the board, and I look forward to collaborating with them, says Joen Averstad, CEO of Hemcheck. 

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.